GERN – Geron Corporation

GERN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

11.14

Margin Of Safety %

Put/Call OI Ratio

0.31

EPS Next Q Diff

0.02

EPS Last/This Y

0.11

EPS This/Next Y

0.08

Price

1.48

Target Price

4.25

Analyst Recom

1.4

Performance Q

1.37

Upside

-336.5%

Beta

0.62

Ticker: GERN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	GERN	1.415	0.34	0.37	59140
2026-07-14	GERN	1.38	0.34	0.18	59151
2026-07-15	GERN	1.425	0.34	0.23	59321
2026-07-16	GERN	1.425	0.34	0.09	59406
2026-07-17	GERN	1.435	0.34	0.03	59365
2026-07-20	GERN	1.44	0.35	0.00	57836
2026-07-21	GERN	1.44	0.35	0.53	58438
2026-07-22	GERN	1.415	0.35	0.20	58630
2026-07-23	GERN	1.445	0.35	0.00	58694
2026-07-24	GERN	1.42	0.35	0.07	59248
2026-07-27	GERN	1.49	0.35	0.01	59269
2026-07-28	GERN	1.455	0.34	0.01	59693
2026-07-29	GERN	1.415	0.34	0.01	59763
2026-07-30	GERN	1.335	0.34	0.31	59828
2026-07-31	GERN	1.295	0.34	0.01	59897
2026-08-03	GERN	1.285	0.34	0.01	60472
2026-08-04	GERN	1.345	0.34	0.03	60586
2026-08-05	GERN	1.625	0.33	0.04	61138
2026-08-06	GERN	1.54	0.31	0.09	66090
2026-08-07	GERN	1.48	0.31	0.06	66115
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	GERN	1.41	-	35.8	-0.02
2026-07-14	GERN	1.38	-	35.8	-0.02
2026-07-15	GERN	1.43	-	36.3	-0.02
2026-07-16	GERN	1.42	-	36.3	-0.02
2026-07-17	GERN	1.43	50.0	36.3	-0.02
2026-07-20	GERN	1.44	50.0	36.3	-0.02
2026-07-21	GERN	1.45	50.0	36.3	-0.02
2026-07-22	GERN	1.41	50.0	36.3	-0.02
2026-07-23	GERN	1.45	50.0	36.3	-0.02
2026-07-24	GERN	1.43	50.0	36.3	-0.02
2026-07-27	GERN	1.49	50.0	36.3	-0.02
2026-07-28	GERN	1.46	50.0	36.3	-0.02
2026-07-29	GERN	1.41	50.0	36.3	-0.02
2026-07-30	GERN	1.34	50.0	36.3	-0.02
2026-07-31	GERN	1.29	50.0	36.3	-0.02
2026-08-03	GERN	1.28	50.0	36.3	-0.02
2026-08-04	GERN	1.28	50.0	36.3	-0.02
2026-08-05	GERN	1.62	50.0	36.5	-0.02
2026-08-06	GERN	1.57	50.0	36.3	-0.02
2026-08-07	GERN	1.48	50.0	21.2	-0.02
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	GERN	-0.07	-0.50	12.78
2026-07-14	GERN	-0.07	-0.50	12.78
2026-07-15	GERN	-0.07	-0.50	12.78
2026-07-16	GERN	-0.07	-0.50	12.78
2026-07-17	GERN	-0.07	-0.50	12.78
2026-07-20	GERN	-0.07	-0.50	12.78
2026-07-21	GERN	-0.07	-0.50	12.78
2026-07-22	GERN	-0.07	-0.50	12.78
2026-07-23	GERN	-0.07	-0.50	12.78
2026-07-24	GERN	-0.07	-0.50	12.78
2026-07-27	GERN	-0.07	-0.49	11.14
2026-07-28	GERN	-0.07	-0.49	11.14
2026-07-29	GERN	-0.07	-0.49	11.14
2026-07-30	GERN	-0.07	-0.49	11.14
2026-07-31	GERN	-0.07	-0.49	11.14
2026-08-03	GERN	-0.07	0.44	11.14
2026-08-04	GERN	-0.07	0.44	11.14
2026-08-05	GERN	-0.07	0.44	11.14
2026-08-06	GERN	-0.07	0.44	11.14
2026-08-07	GERN	-0.07	0.44	11.14
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.02

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

-0.01

Insider Transactions

-0.07

Institutional Transactions

0.44

Beta

0.62

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

72.4

Max Drawdown 5-Year %

-79

Target Price

4.25

P/E

Forward P/E

PEG

P/S

4.65

P/B

4.35

P/Free Cash Flow

EPS

-0.1

Average EPS Est. Cur. Y

-0.02

EPS Next Y. (Est.)

0.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-34.17

Relative Volume

0.67

Return on Equity vs Sector %

-58.3

Return on Equity vs Industry %

-42.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

21.2

◆ GERN Healthcare

$1.48

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

11/25

Volume

9/15

Valuation

15/20

TP/AR

3/10

Options

8/10

RSI

54.3

Range 1M

65.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

21/30

Estimates

4/20

Inst/Vol

4/15

Options

8/10

EPS Yr

67.3%

EPS NY

274.1%

52W%

46.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +83.4% upside

Quality

6/30

Valuation

16/30

Growth

15/25

Stability

5/10

LT Trend

0/5

Upside

+83.4%

Quality

GERN — P/E HistoricalBiotechnology

Geron Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 258

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

GERN

Latest News

—

Caricamento notizie per GERN…

stock quote shares GERN – Geron Corporation Stock Price stock today

news today GERN – Geron Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch GERN – Geron Corporation yahoo finance google finance

stock history GERN – Geron Corporation invest stock market

stock prices GERN premarket after hours

ticker GERN fair value insiders trading

GERN – Geron Corporation

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GERN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y